PIK3CA encodes the p110α catalytic subunit of phosphoinositide 3-kinase (PI3K), an enzyme that converts the membrane lipid PIP2 into PIP3, thereby activating signaling cascades such as the AKT-mTOR pathway that promote cell survival, proliferation, growth, and motility. It is among the most commonly mutated genes in cancer, and aberrant activation of PI3K signaling is a driving event in tumor development, with the gene implicated in cancers including cervical cancer. Because this pathway is central to tumor growth, it is a major target of cancer therapies, although drug-induced pathway activation can also contribute to treatment resistance.

PIK3CA encodes the p110α catalytic subunit of PI3K, a cancer driver whose aberrant activation fuels tumor growth via the AKT-mTOR pathway. A VUS for c.317G>C (p.Gly106Ala) means current evidence cannot establish whether this missense change alters PI3K signaling; it meets neither pathogenic nor benign criteria and should not be assumed to drive disease.